HARBOR Trademark

Trademark Overview

On Thursday, January 4, 2024, a trademark application was filed for HARBOR with the United States Patent and Trademark Office. The USPTO has given the HARBOR trademark a serial number of 98342071. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, May 12, 2026. This trademark is owned by Avidity Biosciences, Inc.. The HARBOR trademark is filed in the Pharmaceutical Products category with the following description:

Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, psychiatric and immune system related diseases and disorders; all of the foregoing excluding therapeutic pharmaceuticals for hair growth, skin health, and sexual dysfunction and compounded pharmaceuticals
harbor

General Information

Serial Number98342071
Word MarkHARBOR
Filing DateThursday, January 4, 2024
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, May 12, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 18, 2025

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of HARBOR text with the "O" as a helm and 3 parallel wavy lines underneath it.
Goods and ServicesTherapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, psychiatric and immune system related diseases and disorders; all of the foregoing excluding therapeutic pharmaceuticals for hair growth, skin health, and sexual dysfunction and compounded pharmaceuticals

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, January 4, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAvidity Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
US
Party NameAvidity Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
US

Trademark Events

Event DateEvent Description
Thursday, January 4, 2024NEW APPLICATION ENTERED
Sunday, April 28, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, April 28, 2024NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, July 31, 2024ASSIGNED TO EXAMINER
Wednesday, August 7, 2024NON-FINAL ACTION WRITTEN
Wednesday, August 7, 2024NON-FINAL ACTION E-MAILED
Wednesday, August 7, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 5, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, November 5, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, February 5, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 5, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 5, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 24, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 12, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 18, 2025PUBLISHED FOR OPPOSITION
Tuesday, March 18, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 13, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, September 5, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, September 5, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, September 5, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 17, 2025SOU TEAS EXTENSION RECEIVED
Thursday, March 5, 2026TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, March 5, 2026APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, March 5, 2026TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, March 5, 2026ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, March 5, 2026TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 7, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 8, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, May 5, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, October 17, 2025TEAS REQUEST TO DIVIDE RECEIVED
Friday, October 17, 2025DIVISIONAL REQUEST RECEIVED
Wednesday, May 6, 2026DIVISIONAL PROCESSING COMPLETE
Thursday, October 16, 2025SOU EXTENSION 1 FILED
Wednesday, May 6, 2026SOU EXTENSION 1 GRANTED
Wednesday, May 6, 2026REVIEW OF CORRESPONDENCE COMPLETE
Wednesday, May 6, 2026CORRECTED NOA E-MAILED
Thursday, May 7, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 11, 2026SOU TEAS EXTENSION RECEIVED
Sunday, May 10, 2026SOU EXTENSION 2 FILED
Tuesday, May 12, 2026SOU EXTENSION 2 GRANTED
Wednesday, May 13, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

harbor based therapies diseases conjugate oligonucleotide pharmaceuticals muscle therapeutic antibody related